See how Precigen's earnings swing compares to peers by reviewing a curated set of 19 high quality undiscovered gems that the market may not be fully focused on yet.
To own Precigen, you need to believe PAPZIMEOS can sustain meaningful, real world use in recurrent respiratory papillomatosis and that the current commercial buildout eventually earns its keep. The swing to a US$35.77 million quarterly profit helps that story but does not remove execution risk around payer processes, physician adoption, and manufacturing scale up.
The analyst consensus Narrative on Simply Wall St leans on a transition to stronger earnings and cash flow, and the latest results support that direction without settling the debate. The biggest near term catalyst still sits with continued PAPZIMEOS uptake and reimbursement consistency. The main risk remains slower than expected patient pull through, which could leave fixed costs heavy.
The most relevant development here is Precigen’s move from a sizeable loss a year ago to US$47.91 million in net income over the first nine months of 2026. This shift lines up with the earlier idea that PAPZIMEOS could move the group toward breakeven using its own cash generation rather than repeated capital raises.
In terms of catalysts, that profit profile gives management more room to execute on pediatric RRP and EMA expansion plans highlighted in the analyst consensus Narrative on Simply Wall St. Investors still need to watch how much of this income is cash based versus non cash, how debt coverage evolves, and whether payer discounts squeeze margins as volumes build.
Precigen's current analyst narrative points to forecast revenue of US$654.3 million and earnings of US$393.8 million by 2029. That scenario implies revenue growing at 96.9% per year and an earnings swing of about US$730.5 million from a loss of US$336.7 million today to the 2029 consensus figure.
Uncover why Precigen's fair value indicates a 201% potential upside to its current price, which could narrow quickly.
One alternate view on Precigen puts reimbursement risk at the center. The most cautious analysts were pencilling in revenue of about US$480.3 million and earnings of roughly US$454.5 million by 2029 before this latest profit swing. That camp expects tighter payer terms, so you see how opinions can differ sharply.
Explore 2 other Precigen fair value estimates, including one that suggests it could be worth just $13.65!
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
If this Precigen update has sharpened your view on risk, reward, and timing, it can help to line it up against a broader watchlist. Use the Simply Wall St Screener to compare this story with other opportunities that match your preferred style of investing.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com